Indivior PLC

Fundamentals4.0
Price Action6.0
News Sentiment7.0
AI Rating
6.0

Key Drivers

  • High gross margin
  • Negative equity
  • Negative FCF

AI
AI Summary

6.0

Indivior is now a high‑conviction, SUBLOCADE‑centric profitability bet—its attractive ~80% gross margins and targeted $150M OpEx cuts can drive EBITDA and FCF upside, but the investment hinges on execution-driven cash conversion rather than pipeline optionality. Investors should watch for sustainably positive operating cash flow and improving working capital within 2–4 quarters (or clearer payer/access wins) as the specific trigger for re-rating; failure to deliver would magnify dilution, solvency, and single‑product risk.

MarginLeverage
LiquidityRisk
Execution‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

4.0

Key Financial Insights:

  • High gross margin
  • Negative equity
  • Negative FCF

INDV shows strong reported profitability and unit economics but faces acute liquidity strain, negative equity and persistent negative free cash flow that materially elevate balance-sheet and cash-generation risk.

liquidity
profitability

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Below last-month SMA
  • Support at ~$29.3
  • Resistance cluster ~$31–$33.5

Price is in a short-term downtrend, trading ~8–9% below its last-month SMA (~$32.03) with bearish momentum (RSI ~35) and a key near-term support at ~$29.30 that, if broken, would raise downside risk while reclaiming $31.0–$33.5 is needed to confirm a reversal.

Bearish
Watchlist
Support Level: $29.30
Resistance Level: $31.0–$33.5

Price fell ~12% from $33.34 on 2026-03-10 to $29.31 on 2026-03-20, indicating heightened short-term volatility

Sentiment & News

7.0

Key News Insights:

  • Convertible upsized
  • Positive adherence
  • Correctional access

Between late Feb and mid‑Mar 2026 Indivior reported FY2025 results, engaged investors, upsized a $450M convertible note, and released SUBLOCADE adherence data while highlighting persistent correctional access gaps.

capitalraise
access

The $450M convertible strengthens liquidity and supports commercialization/clinical plans, and favorable adherence data boosts product value, but correctional access gaps could constrain uptake